Company Overview - Longevity Health Holdings, Inc. (XAGE) focuses on advancing human longevity and healthy aging through regenerative bio-aesthetics, diagnostics, and nutrition [1][3] - The company offers two regenerative technologies: Carmell Secretome™ and Elevai Exosomes™, aimed at improving skin and hair health [3] Recent Financial Activity - XAGE successfully sold 479,621 shares of common stock at an average price of $4.08 per share, generating gross proceeds of approximately $1.96 million before fees and expenses [1] - This financing extends XAGE's cash runway into Q1 FY26, assuming no growth beyond the pro forma consolidated FY24 sales and not factoring in the planned merger with 20/20 [2] Strategic Developments - The company is moving forward with a planned merger with 20/20 BioLabs, which develops innovative laboratory tests for chronic disease risk management [3][4] - The successful ATM offering reflects continued investor confidence in XAGE's vision and growth strategy, as stated by the CEO Rajiv Shukla [3]
Longevity Health Holdings, Inc. Announces Successful Fundraising Via ATM Sale
Globenewswire·2025-05-27 13:20